Movement Alert｜ASYMCHEM Rises 3.64% in Regular Trading, CRO Sector Continues Rally on Strong Order Growth and Industry Upgrade Cycle

Market Focus09-18

On September 18, ASYMCHEM rose 3.64% in regular trading, trading at 166.0 HKD/share, with turnover of 11.28 million HKD, extending a multi-day rally in the CRO sector.

On the news front, Goldman Sachs recently published a report affirming its bullish outlook on the recovery trajectory of China's CRO/CDMO industry, with the broader CXO sector posting first-half revenue growth exceeding 25% and adjusted net profit growth surpassing 66%, confirming the industry's upward cycle. Additionally, AI-driven drug discovery has entered clinical validation stages, with early commercialization momentum further boosting sector sentiment.

At the company level, ASYMCHEM reported first-half revenue of 3.607 billion yuan, up 13.13% year-over-year, with in-hand orders surging 54% and new orders growing 55%. Emerging business revenue jumped 72.49%, with gross margin improving to 32.5%. Management maintained full-year revenue growth guidance of 19%-22%, with approximately 85% of in-hand orders expected to convert to revenue in the second half through next year. Kaiyuan Securities assigned a Buy rating, projecting earnings per share of 4.18/5.15/6.41 yuan for the next three fiscal years.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156930915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156930915","market":"us","top_or_hot":-1,"title":"Movement Alert｜ASYMCHEM Rises 3.64% in Regular Trading, CRO Sector Continues Rally on Strong Order Growth and Industry Upgrade Cycle","media":"Market Focus","content":"<p><p>On September 18, ASYMCHEM rose 3.64% in regular trading, trading at 166.0 HKD/share, with turnover of 11.28 million HKD, extending a multi-day rally in the CRO sector.</p><p>On the news front, Goldman Sachs recently published a report affirming its bullish outlook on the recovery trajectory of China's CRO/CDMO industry, with the broader CXO sector posting first-half revenue growth exceeding 25% and adjusted net profit growth surpassing 66%, confirming the industry's upward cycle. Additionally, AI-driven drug discovery has entered clinical validation stages, with early commercialization momentum further boosting sector sentiment.</p><p>At the company level, ASYMCHEM reported first-half revenue of 3.607 billion yuan, up 13.13% year-over-year, with in-hand orders surging 54% and new orders growing 55%. Emerging business revenue jumped 72.49%, with gross margin improving to 32.5%. Management maintained full-year revenue growth guidance of 19%-22%, with approximately 85% of in-hand orders expected to convert to revenue in the second half through next year. Kaiyuan Securities assigned a Buy rating, projecting earnings per share of 4.18/5.15/6.41 yuan for the next three fiscal years.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ASYMCHEM Rises 3.64% in Regular Trading, CRO Sector Continues Rally on Strong Order Growth and Industry Upgrade Cycle</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ASYMCHEM Rises 3.64% in Regular Trading, CRO Sector Continues Rally on Strong Order Growth and Industry Upgrade Cycle\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-18 09:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 18, ASYMCHEM rose 3.64% in regular trading, trading at 166.0 HKD/share, with turnover of 11.28 million HKD, extending a multi-day rally in the CRO sector.</p><p>On the news front, Goldman Sachs recently published a report affirming its bullish outlook on the recovery trajectory of China's CRO/CDMO industry, with the broader CXO sector posting first-half revenue growth exceeding 25% and adjusted net profit growth surpassing 66%, confirming the industry's upward cycle. Additionally, AI-driven drug discovery has entered clinical validation stages, with early commercialization momentum further boosting sector sentiment.</p><p>At the company level, ASYMCHEM reported first-half revenue of 3.607 billion yuan, up 13.13% year-over-year, with in-hand orders surging 54% and new orders growing 55%. Emerging business revenue jumped 72.49%, with gross margin improving to 32.5%. Management maintained full-year revenue growth guidance of 19%-22%, with approximately 85% of in-hand orders expected to convert to revenue in the second half through next year. Kaiyuan Securities assigned a Buy rating, projecting earnings per share of 4.18/5.15/6.41 yuan for the next three fiscal years.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06821","symbol_name":"凯莱英","start_time":0,"source_url":"","article_id":"1156930915","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156930915","pubTimestamp":1789695340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 18, ASYMCHEM rose 3.64% in regular trading, trading at 166.0 HKD/share, with turnover of 11.28 million HKD, extending a multi-day rally in the CRO sector.On the news front, Goldman Sachs...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06821":"凯莱英"},"translate_title":"走势提醒|凯莱英常规交易上涨3.64%，CRO板块在订单强劲增长和行业升级周期下继续上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06821":1},"content_text":"On September 18, ASYMCHEM rose 3.64% in regular trading, trading at 166.0 HKD/share, with turnover of 11.28 million HKD, extending a multi-day rally in the CRO sector.On the news front, Goldman Sachs recently published a report affirming its bullish outlook on the recovery trajectory of China's CRO/CDMO industry, with the broader CXO sector posting first-half revenue growth exceeding 25% and adjusted net profit growth surpassing 66%, confirming the industry's upward cycle. Additionally, AI-driven drug discovery has entered clinical validation stages, with early commercialization momentum further boosting sector sentiment.At the company level, ASYMCHEM reported first-half revenue of 3.607 billion yuan, up 13.13% year-over-year, with in-hand orders surging 54% and new orders growing 55%. Emerging business revenue jumped 72.49%, with gross margin improving to 32.5%. Management maintained full-year revenue growth guidance of 19%-22%, with approximately 85% of in-hand orders expected to convert to revenue in the second half through next year. Kaiyuan Securities assigned a Buy rating, projecting earnings per share of 4.18/5.15/6.41 yuan for the next three fiscal years.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156930915","isCrawlerRequest":true}